卡巴他赛在伴或不伴DNA损伤修复缺陷的转移性去势抵抗性前列腺癌男性中的活性
这项回顾性多中心研究纳入190例接受卡巴他赛治疗且完成DDR组织检测的mCRPC患者(95例DDR+,95例DDR-配对),DDR+与DDR-的PSA50分别为32%与36%(P=0.64),中位rPFS分别为5.33个月与5.75个月(P=0.55),中位OS分别为15.4个月与11.5个月(P=0.036)。作者认为卡巴他赛活性与DDR状态无关,但既往接受PARPi者活性可能较低。
要点
- DDR+与DDR-患者卡巴他赛的PSA50分别为32%与36%,差异无统计学意义(P=0.64)。
- DDR+与DDR-的中位rPFS分别为5.33个月与5.75个月,差异无统计学意义(P=0.55)。
- DDR+与DDR-的中位OS分别为15.4个月与11.5个月(P=0.036)。
核心结论
- 作者认为卡巴他赛在mCRPC患者中具有活性,无论其DDR状态如何,但既往接受PARPi治疗者活性可能较低。
研究设计与样本
- 回顾性多中心研究,纳入接受卡巴他赛治疗且完成DDR肿瘤组织检测的mCRPC患者,DDR+与同机构DDR-患者按1:1配对。
- 组织测序队列共190例(95例DDR+,95例DDR-),另设液体活检DDR+探索性队列63例。
主要发现
- DDR+与DDR-的PSA50分别为29/92(32%)与33/92(36%),P=0.64。
- DDR+与DDR-的中位rPFS分别为5.33个月(95%CI 4.34-7.04)与5.75个月(95%CI 4.67-7.27),P=0.55。
- DDR+与DDR-的中位OS分别为15.4个月(95%CI 12.16-26.6)与11.5个月(95%CI 9.76-14.4),P=0.036。
- 既往接受PARPi治疗的BRCA1/2患者(n=10)中未观察到卡巴他赛的PSA50应答。
- 液体活检DDR+队列(n=63)中卡巴他赛的结局相似。
临床怎么用
- 作者认为卡巴他赛在mCRPC患者中具有活性,无论其DDR状态如何,但既往接受PARPi治疗者活性可能较低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cabazitaxel was shown to improve overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) after abiraterone/enzalutamine and docetaxel failure, though benefit by the presence of DNA damage repair (DDR) defects is unknown. With the advent of poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) in partially overlapping indications with cabazitaxel, we aimed to determine cabazitaxel activity in men with mCRPC according to their DDR status. METHODS: This is a retrospective multicenter study that enrolled patients with mCRPC treated with cabazitaxel who had undergone DDR tumour tissue profiling. Patients with at least one deleterious germline or somatic alterations were considered DDR positive (DDR+). Each DDR + patient has been matched with a DDR negative (DDR-) from the same institution who underwent the same test. An exploratory cohort of patients found to be DDR + by liquid biopsy was also included. Prostate specific antigen (PSA) decline≥50% (PSA50), PSA progression-free survival (PFS, PSA-PFS), radiographic PFS (rPFS), clinical PFS or radiographic PFS (c/rPFS) and OS were evaluated. RESULTS: Among 190 men (95 DDR+, 95 DDR-) with tissue sequencing, PSA50 was achieved with cabazitaxel in 29/92 (32%) and 33/92 (36%) in patients with DDR+ and DDR- (P = 0.64). The median rPFS was 5.33 months [95%CI 4.34-7.04] versus 5.75 months [95%CI 4.67-7.27] (P = 0.55). The median OS was 15.4 months [95%CI 12.16-26.6] and 11.5 months [95%CI 9.76-14.4] (P = 0.036), respectively. No PSA50 responses on cabazitaxel were observed in BRCA1/2 patients previously treated with PARPi (n = 10). Similar outcomes with cabazitaxel were observed in the liquid biopsy cohort (n = 63 DDR+). CONCLUSIONS: Our study suggests that cabazitaxel is active in patients with mCRPC regardless of their DDR status, although its activity in men pretreated with a PARPi may be lower.
引用
- Aldea M, Lam L, Orillard E, et al. Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects. Eur J Cancer. 2021. PMID: 34742160. doi:10.1016/j.ejca.2021.09.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。